Immuno-Oncology

Drug That Boosts Immunotherapy Studied as Tool to Battle COVID-19 in Patients With Cancer

October 30th 2020, 4:00am

Article

An investigational drug, IMM-101, already being studied for its ability to increase the effects of immuno-oncology agents, may be able to prevent or lessen the effects of COVID-19 among those with cancer.

Best Cancer Tests Don't Reach All Who Need Them

August 17th 2020, 9:15am

Article

Evidence-Based Oncology managed care updates for August 2020 feature coverage of liquid biopsies, companion diagnostics, and CAR T-cell therapy.

The Promise of Specialty Oncology Innovations in the Drug Pipeline

May 1st 2019, 7:11pm

Article

The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at Asembia's 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas.

Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer

April 12th 2019, 5:00pm

Video

The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.

Cost Differential of Immuno-Oncology Therapy Delivered at Community Versus Hospital Clinics

March 7th 2019, 10:00pm

Article

Administration of immuno-oncology therapy for cancer diagnoses in the community clinic setting is associated with lower costs compared with administration in a hospital-based clinic setting.

This Week in Managed Care: February 15, 2019

February 15th 2019, 7:23pm

Video

This week, the top managed care news included increased demand for long-acting contraception since President Trump took office; a payer decision on an insulin pump alarmed diabetes advocates; and despite being involved in cancer treatment decisions, many primary care providers don't feel prepared to do so.

Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma

February 14th 2019, 1:13am

Article

Evidence-Based OncologyTM recently sat down with Rodabe Amaria, MD, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine, at MD Anderson and a lead author on a study that found that evidence has been accumulating in preclinical models that neoadjuvant treatment may be superior to treatment after surgery for patients with advanced melanoma.

Is Immunotherapy the Future of Glioblastoma Treatment?

February 13th 2019, 12:49am

Article

Immunotherapy has seen great success in the treatment of numerous cancers, from melanoma to lung, breast, colorectal, kidney, and even some brain cancers. But thus far, despite several attempts, the devastating brain disease glioblastoma has not been among the immunotherapy success stories. In fact, glioblastoma researchers have had few advances in more than a decade.

Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy

January 19th 2019, 7:00pm

Article

Higher tumor mutational burden is associated with improved overall survival in patients with stage IV or metastatic disease being treated with immune checkpoint inhibitors.

Ted Okon: A Different Reimbursement Approach Is Needed for CAR T, Other Innovative Therapies

December 27th 2018, 7:00pm

Video

As new, innovative therapies with high price tags, such as chimeric antigen receptor (CAR) T-cell therapy, come to market, the US health system will have to start looking at different approaches for reimbursement, said Ted Okon, MBA, executive director of the Community Oncology Alliance.